Compare AdaptHealth Corp (AHCO) vs Amgen, Inc. (AMGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AdaptHealth Corp vs Amgen, Inc. — how do they compare? AdaptHealth Corp trades at $5.75 (market cap $753.09M), while Amgen, Inc. trades at $416.95 (market cap $224.14B). The key difference: Amgen, Inc. is far larger — about 297.6× AdaptHealth Corp's market cap, and Amgen, Inc. pays a 2.43% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | AMGN | |
|---|---|---|
Market Cap | $753.09M | $224.14B |
Sector | Health | Health |
52-Week High | $13.38 | $417.20 |
52-Week Low | $5.22 | $271.18 |
Enterprise Value | $2.77B | $267.45B |
Dividend Yield | — | 2.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AdaptHealth Corp. (AHCO) trades at $5.74, up 9.96% in the last session, yet remains under pressure with a bearish technical signal and recent earnings misses. The company reported a Q2 2026 net loss of $228 million with a -6.82% margin, while selling its diabetes unit to focus on sleep and respiratory care. Valuation ratios show a low P/S of 0.23 and P/B of 0.55, but negative profitability metrics highlight operational challenges.
The outlook is mixed: analyst consensus is bullish with a $11 price target, but risks include ongoing losses, fraud investigations, and cost overruns in fixed-price contracts. Upside depends on successful business restructuring and margin improvement, while downside risks from legal and execution issues persist.
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AdaptHealth Corp
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →
